Hormonal
Weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle interventions produces clinically significant weight loss (mean -14.9%) in adults with obesity, outperforming daily liraglutide (3.0 mg) in magnitude and duration of effect.
If you have obesity, weekly semaglutide injections (2.4 mg) combined with diet and exercise can help you lose nearly 15% of your body weight. This is significantly more effective than daily liraglutide. Start with a low dose to minimize nausea, and stick with it, as the benefits persist longer than other treatments.
In the clinical trials that compared GLP-1 agonists to placebo, it was observed that semaglutide was associated with more weight loss than liraglutide, and this loss persisted for a longer period of time.
Why this rating
Based on multiple randomized controlled trials (STEP 3, SCALE) with large sample sizes, though the paper is a literature review.
Source
O USO DE ANÁLOGOS DE GLP-1 LIRAGLUTIDA, SEMAGLUTIDA E TIRZEPATIDA NO TRATAMENTO DA OBESIDADE: UMA REVISÃO DE LITERATURA
Bruna Machado Staico et al. · RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218 · 2023
DOI 10.47820/recima21.v4i4.2950
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →